News

US awards $3.4 million for S. aureus vaccine

Country
Switzerland

The US National Institutes of Health have awarded $3.4 million to GlycoVaxyn AG of Switzerland and a researcher at the Harvard Medical School to carry out preclinical work on a new S. aureus vaccine for hospital-acquired infections.

 

FDA approves first-ever cellular immunotherapy

Country
United States

The US Food and Drug Administration has issued its first-ever approval of a cellular immunotherapy. The product, Provenge (sipuleucel-T), is a therapeutic vaccine developed by Dendreon Corp of Seattle, Washington.

Affimed raises €20 million in Series C round

Country
Germany

Affimed Therapeutics AG of Germany has raised €20 million in a Series C round to bring it antibody candidate for Hodgkin’s lymphoma into the clinic and develop its pipeline. The round was led by existing investors including Novo Nordisk A/S.

Bicycle Therapeutics obtains seed funding from SR One

Country
United Kingdom

Bicycle Therapeutics Ltd, which is developing a new peptide technology, has completed its seed funding round having raised new money from SR One, the venture capital arm of GlaxoSmithKline, and SV Life Sciences. The sums were not disclosed.

AstraZeneca revises financial target upward

Country
United Kingdom

AstraZeneca has revised upward its per-share earnings forecast for 2010 even though revenue growth may be constrained by expected generic competition for the breast cancer drug, Arimidex, and lower pandemic flu vaccine sales.

Sanofi-Aventis advances new strategy in first quarter

Country
France

Sanofi-Aventis continued to diversify into consumer healthcare and the emerging markets in the 2010 first quarter, while also strengthening its franchise in diabetes with the signing of partnerships in glucose monitoring and diabetes research.

The French multinational gave an update on its new strategic direction with the release of its 2010 first quarter results on 29 April.

 

GSK continued to diversify in Q1

Country
United Kingdom

GlaxoSmithKline Plc reported a rise in turnover of 13%, at constant exchange rates, in the first quarter, driven by sales of anti-viral and pandemic influenza products. Sales in western markets meanwhile contributed less to the total, than a year ago.

Modern insulins drive growth at Novo Nordisk

Country
Denmark

Novo Nordisk A/S said that modern insulins drove growth in the first quarter when sales, in local currencies, rose by 11% to DKK13.7 million (€1.84 million). At the end of the quarter, the Danish company claimed 51% of the global insulin market.

Cellular Dynamics raises $40.6 million for cell technology

Country
United States

Cellular Dynamics International (CDI) Inc of Madison, Wisconsin has raised $40.6 million in a Series B private equity round to increase production capacity for its human heart cells derived from induced pluripotent stem cells (IPSCs).

MorphoSys confirms 2010 revenue and profit targets

Country
Germany

MorphoSys AG has confirmed that it expects to report revenue of between €89 to €93 million in 2010, up from €81 million in 2009, and to report an operating profit of €5 to €9 million, compared with €11.4 million the previous year.